Mitoconix Bio Company

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).

Last Funding Type: Venture - Series Unknown
Total Funding: $54.2M
Estimated Revenue: Less than $1M
Technology: Other
Investors Number: 6
Founded Date: 2016
Headquarters: Israel
Industry: Mitochondrial Dynamics